Keros Therapeutics, Inc. (NASDAQ:KROS) Receives $30.00 Average PT from Brokerages

Key Points

• Keros Therapeutics, Inc. has received a consensus rating of "Moderate Buy" from 14 brokerages, with an average price target of $30.00.
• The company's recent quarterly earnings report showed an EPS of ($0.76), beating expectations of ($1.14), but with revenue significantly below estimates at $0.02 million.
• Institutional investors hold 71.56% of Keros Therapeutics stock, indicating strong interest from major financial entities.

Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) has been given a consensus rating of "Moderate Buy" by the fourteen analysts that are covering the firm, Marketbeat reports. Seven analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year price target among analysts that have covered the stock in the last year is $30.00.

Several analysts recently commented on the stock. Scotiabank dropped their price target on shares of Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating on the stock in a research report on Monday, May 12th. Bank of America lowered shares of Keros Therapeutics from a "buy" rating to a "neutral" rating and dropped their target price for the company from $32.00 to $18.00 in a research report on Tuesday, June 10th. Wedbush reiterated a "neutral" rating and issued a $15.00 target price on shares of Keros Therapeutics in a research report on Friday, May 30th. Finally, HC Wainwright dropped their target price on shares of Keros Therapeutics from $25.00 to $20.00 and set a "buy" rating on the stock in a research report on Friday, August 8th.

Keros Therapeutics Price Performance

KROS stock traded down $0.04 during midday trading on Monday, hitting $15.21. 586,020 shares of the stock traded hands, compared to its average volume of 484,760. The firm has a market cap of $617.83 million, a P/E ratio of 49.07, a PEG ratio of 1.97 and a beta of 1.33. The stock's fifty day simple moving average is $14.20 and its 200-day simple moving average is $13.13. Keros Therapeutics has a 1-year low of $9.12 and a 1-year high of $72.37.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.76) EPS for the quarter, beating the consensus estimate of ($1.14) by $0.38. The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $3.83 million. Keros Therapeutics had a net margin of 8.06% and a return on equity of 2.96%. The firm's revenue was up 49002.7% on a year-over-year basis. During the same quarter last year, the business earned ($1.25) earnings per share. On average, research analysts predict that Keros Therapeutics will post -4.74 earnings per share for the current year.

Institutional Trading of Keros Therapeutics

Institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC grew its position in shares of Keros Therapeutics by 7,690.3% in the first quarter. GAMMA Investing LLC now owns 2,415 shares of the company's stock valued at $237,000 after purchasing an additional 2,384 shares during the period. FNY Investment Advisers LLC acquired a new stake in shares of Keros Therapeutics in the first quarter valued at about $25,000. CWM LLC lifted its stake in shares of Keros Therapeutics by 10,157.7% in the first quarter. CWM LLC now owns 2,667 shares of the company's stock worth $27,000 after buying an additional 2,641 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Keros Therapeutics by 149.2% in the second quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company's stock worth $42,000 after buying an additional 1,888 shares in the last quarter. Finally, Virtus ETF Advisers LLC lifted its stake in shares of Keros Therapeutics by 107.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company's stock worth $61,000 after buying an additional 1,998 shares in the last quarter. Institutional investors and hedge funds own 71.56% of the company's stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.